Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Harry A. Fagan & David S. Baldwin. (2023) Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions. Expert Review of Neurotherapeutics 23:6, pages 535-548.
Read now
Read now
Susana Barbosa-Méndez, Gilberto Perez-Sánchez & Alberto Salazar-Juárez. (2023) Agomelatine decreases cocaine-induced locomotor sensitisation and dopamine release in rats. The World Journal of Biological Psychiatry 24:5, pages 400-413.
Read now
Read now
Bella Schanzer, Ana Maria Rivas-Grajales, Aamir Khan & Sanjay J Mathew. (2019) Novel investigational therapeutics for generalized anxiety disorder (GAD). Expert Opinion on Investigational Drugs 28:11, pages 1003-1012.
Read now
Read now
Jakub Trawiński & Robert Skibiński. (2019) Photostability study of agomelatine using UHPLC-DAD-MS/MS method. Kinetics, identification of the transformation products and in silico evaluation of toxicity. Journal of Liquid Chromatography & Related Technologies 42:3-4, pages 63-73.
Read now
Read now
Articles from other publishers (40)
Volkan Gelen, Seçkin Özkanlar, Adem Kara & Ali Yeşildağ. (2023)
Citrate‐coated silver nanoparticles loaded with agomelatine provide neuronal therapy in acute cerebral ischemia/reperfusion of rats by inhibiting the oxidative stress, endoplasmic reticulum stress, and
P2X7
receptor‐mediated inflammasome
. Environmental Toxicology.
Crossref
Crossref
Yue-Han Guo, Le Zhou, Zi-Ang Cui, Jian Wang, Lei Zhang, Ting Xu, Yi-Dan XieHui Chen. (2023) Efficacy and safety of agomelatine in the treatment of patients with depressive disorder: A meta-analysis. Medicine 102:45, pages e35871.
Crossref
Crossref
Rosa Savino, Anna Nunzia Polito, Gabriella Marsala, Antonio Ventriglio, Melanie Di Salvatore, Maria Ida De Stefano, Anna Valenzano, Luigi Marinaccio, Antonello Bellomo, Giuseppe Cibelli, Marcellino Monda, Vincenzo Monda, Antonietta Messina, Rita Polito, Marco Carotenuto & Giovanni Messina. (2023) Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders. Brain Sciences 13:5, pages 734.
Crossref
Crossref
Mei Gao, Kai Chen, Wei Gu, Xiaoyu Liu, Tianbin Liu, Yong Ying, Chong Cao, Yanhua Zhang, Daizhou Zhang & Guiwen Yang. (2022) 28‐day repeated dose toxicity and toxicokinetics study on new melatonergic antidepressant GW117 in beagle dogs. Journal of Applied Toxicology 43:4, pages 577-588.
Crossref
Crossref
Başaran KARADEMİR. (2023) The assessment of effectiveness of a novel antidepressant, Agomelatine on anxiety and depression induced by fluoride intoxication by means of Open-Field and Hot-Plate tests in mouse model (BalB-C). Ankara Üniversitesi Veteriner Fakültesi Dergisi 70:2, pages 123-130.
Crossref
Crossref
Alice Caldiroli, Lia Colzani, Enrico Capuzzi, Cecilia Quitadamo, Davide La Tegola, Teresa Surace, Stefania Russo, Mauro Capetti, Silvia Leo, Agnese Tringali, Matteo Marcatili, Francesco Zanelli Quarantini, Fabrizia Colmegna, Antonios Dakanalis, Massimiliano Buoli & Massimo Clerici. (2023) Clinical Markers of Panic and Generalized Anxiety Disorder: Overlapping Symptoms, Different Course and Outcome. Journal of Personalized Medicine 13:3, pages 491.
Crossref
Crossref
Zhengping Pu, Qingmei Hou, Hui Yan, Yong Lin & Zilei Guo. (2023) Efficacy of repetitive transcranial magnetic stimulation and agomelatine on sleep quality and biomarkers of adult patients with mild to moderate depressive disorder. Journal of Affective Disorders 323, pages 55-61.
Crossref
Crossref
Qiang Su, Tian Li, Guo-Wei Liu, Yan-Li Zhang, Jun-Hong Guo, Zhao-Jun Wang, Mei-Na Wu & Jin-Shun Qi. (2023) Agomelatine: a potential novel approach for the treatment of memory disorder in neurodegenerative disease. Neural Regeneration Research 18:4, pages 727.
Crossref
Crossref
Alexander T Gallo, Stephen Addis, Vlad Martyn, Hishani Ramanathan, Grace K Wilkerson, Kellie S Bennett, Sean D Hood, Hans Stampfer & Gary K Hulse. (2023) The role of flumazenil in generalised anxiety disorder: a pilot naturalistic open-label study with a focus on treatment resistance. Therapeutic Advances in Psychopharmacology 13, pages 204512532311564.
Crossref
Crossref
Muhammad Naveed, Lian-Di Li, Gang Sheng, Zi-Wei Du, Ya-Ping Zhou, Sun Nan, Ming-Yi Zhu, Jing Zhang & Qi-Gang Zhou. (2022) Agomelatine: An Astounding Sui-generis Antidepressant?. Current Molecular Pharmacology 15:7, pages 943-961.
Crossref
Crossref
Marco Reschini, Massimiliano Buoli, Federica Facchin, Alessia Limena, Chiara Dallagiovanna, Valentina Bollati & Edgardo Somigliana. (2022) Women’s quality of sleep and in vitro fertilization success. Scientific Reports 12:1.
Crossref
Crossref
Alexander T Gallo & Gary K Hulse. (2022) A theory of the anxiolytic action of flumazenil in anxiety disorders. Journal of Psychopharmacology 36:4, pages 439-448.
Crossref
Crossref
Wijitra Chumboatong, Satchakorn Khamchai, Chainarong Tocharus, Piyarat Govitrapong & Jiraporn Tocharus. (2021) Agomelatine Exerts an Anti-inflammatory Effect by Inhibiting Microglial Activation Through TLR4/NLRP3 Pathway in pMCAO Rats. Neurotoxicity Research 40:1, pages 259-266.
Crossref
Crossref
Silvia Mariel Ferrucci, Simona Tavecchio, Luisa Angileri, Teresa Surace, Emilio Berti & Massimiliano Buoli. (2021) Factors Associated with Affective Symptoms and Quality of Life in Patients with Atopic Dermatitis. Acta Dermato-Venereologica 101:11, pages adv00590.
Crossref
Crossref
Najiao Hong, Zhirong Ye, Yongjun Lin, Wensen Liu, Na Xu & Yan Wang. (2021) Agomelatine prevents angiotensin II-induced endothelial and mononuclear cell adhesion. Aging 13:14, pages 18515-18526.
Crossref
Crossref
Alena Shalimova, Viktoria Babasieva, Vladimir N Chubarev, Vadim V Tarasov, Helgi B Schiöth & Jessica Mwinyi. (2021) Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics. Pharmacogenomics 22:8.
Crossref
Crossref
Gustavo R. Villas-Boas, Stefânia N. Lavorato, Marina M. Paes, Pablinny M. G. de Carvalho, Vanessa C. Rescia, Mila S. Cunha, Manoel F. de Magalhães-Filho, Luis F. Ponsoni, Adryano Augustto Valladao de Carvalho, Roseli B. de Lacerda, Lais da S. Leite, Matheus da S. Tavares-Henriques, Luiz A. F. Lopes, Luiz G. R. Oliveira, Saulo E. Silva-Filho, Ana P. S. da Silveira, Roberto K. N. Cuman, Francielli M. de S. Silva-Comar, Jurandir F. Comar, Luana do A. Brasileiro, Jussileide N. dos Santos, William R. de Freitas, Katyuscya V. Leão, Jonatas G. da Silva, Raphael C. Klein, Mary H. F. Klein, Bruno H. da S. Ramos, Cristiane K. C. Fernandes, Dayane G. de L. Ribas & Silvia A. Oesterreich. (2021) Modulation of the Serotonergic Receptosome in the Treatment of Anxiety and Depression: A Narrative Review of the Experimental Evidence. Pharmaceuticals 14:2, pages 148.
Crossref
Crossref
Kamini Ho Pian & Monique Nederstigt. 2021. Slaapstoornissen in de psychiatrie. Slaapstoornissen in de psychiatrie
229
253
.
Ion-George Anghelescu & Otto Benkert. 2021. Kompendium der Psychiatrischen Pharmakotherapie. Kompendium der Psychiatrischen Pharmakotherapie
451
497
.
Jean A. Boutin, Paula A. Witt‐Enderby, Christoph Sotriffer & Darius P. Zlotos. (2020) Melatonin receptor ligands: A pharmaco‐chemical perspective. Journal of Pineal Research 69:3.
Crossref
Crossref
Anna Haduch, Ewa Bromek, Marta Rysz, Renata Pukło, Mariusz Papp, Piotr Gruca, Magdalena Łasoń, Monika Niemczyk & Władysława A. Daniel. (2020) The effects of agomelatine and imipramine on liver cytochrome P450 during chronic mild stress (CMS) in the rat. Pharmacological Reports 72:5, pages 1271-1287.
Crossref
Crossref
A. Irem Sonmez, Ammar Almorsy, Laura B. Ramsey, Jeffrey R. Strawn & Paul E. Croarkin. (2020) Novel pharmacological treatments for generalized anxiety disorder: Pediatric considerations. Depression and Anxiety 37:8, pages 747-759.
Crossref
Crossref
Eliška Nosková, Antonín Šebela & Pavla Stopková. (2020) Current trends in treatment of generalised anxiety disorder. Psychiatrie pro praxi 21:2, pages 66-72.
Crossref
Crossref
Wijitra Chumboatong, Satchakorn Khamchai, Chainarong Tocharus, Piyarat Govitrapong & Jiraporn Tocharus. (2020) Agomelatine protects against permanent cerebral ischaemia via the Nrf2-HO-1 pathway. European Journal of Pharmacology 874, pages 173028.
Crossref
Crossref
Ruchita Ravindra Dhangar, Pravin Popatrao Kale, Pramod Kerunath Kadu & Kedar Prabhavalkar. (2019) Possible Benefits of Considering Glutamate with Melatonin or Orexin or Oxytocin as a Combination Approach in the Treatment of Anxiety. Current Pharmacology Reports 6:1, pages 1-7.
Crossref
Crossref
Simone B. Sartori & Nicolas Singewald. (2019) Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacology & Therapeutics 204, pages 107402.
Crossref
Crossref
Ting-Ren Chen, Hui-Chuan Huang, Jer-Hwa Hsu, Wen-Chen Ouyang & Kuan-Chia Lin. (2019) Pharmacological and psychological interventions for generalized anxiety disorder in adults: A network meta-analysis. Journal of Psychiatric Research 118, pages 73-83.
Crossref
Crossref
Stefano Comai, Martha Lopez-Canul, Danilo De Gregorio, Ada Posner, Mohamed Ettaoussi, Fabrizia Claudia Guarnieri & Gabriella Gobbi. (2019) Melatonin MT1 receptor as a novel target in neuropsychopharmacology: MT1 ligands, pathophysiological and therapeutic implications, and perspectives. Pharmacological Research 144, pages 343-356.
Crossref
Crossref
Brian H Harvey, Wilmie Regenass, Walter Dreyer & Marisa Möller. (2019) Social isolation rearing-induced anxiety and response to agomelatine in male and female rats: Role of corticosterone, oxytocin, and vasopressin. Journal of Psychopharmacology 33:5, pages 640-646.
Crossref
Crossref
Miriam Saiz-Rodríguez, Dolores Ochoa, Carmen Belmonte, Manuel Román, Danilo Vieira de Lara, Pablo Zubiaur, Dora Koller, Gina Mejía & Francisco Abad-Santos. (2019)
Polymorphisms in
CYP1A2, CYP2C9
and
ABCB1
affect agomelatine pharmacokinetics
. Journal of Psychopharmacology 33:4, pages 522-531.
Crossref
Crossref
Hua Li, Xuhui Li, Wei Luo & Xiaolong Zhu. (2019) (Z)-7,4′-Dimethoxy-6-hydroxy-aurone-4-O-β-glucopyranoside exerts neuroprotective effects in vitro and anxiolytic activity in vivo. NeuroReport 30:4, pages 280-287.
Crossref
Crossref
Jörg Angenendt, Ulrich Frommberger, Mathias Berger & Katharina Domschke. 2019. Psychische Erkrankungen. Psychische Erkrankungen
445
481.e3
.
I.-G. Anghelescu & O. Benkert. 2019. Kompendium der Psychiatrischen Pharmakotherapie. Kompendium der Psychiatrischen Pharmakotherapie
505
554
.
Joseph Wai-Hin Leung, Way Kwok-Wai Lau, Benson W-M. Lau & Benjamin K. Yee. 2019. Psychiatry and Neuroscience Update. Psychiatry and Neuroscience Update
177
186
.
Andreas Ströhle, Jochen Gensichen & Katharina Domschke. (2018) The Diagnosis and Treatment of Anxiety Disorders. Deutsches Ärzteblatt international.
Crossref
Crossref
Özgür Can, Umut Üçel, Ümide Demir Özkay & Emel Ulupınar. (2018) The Effect of Agomelatine Treatment on Diabetes-Induced Cognitive Impairments in Rats: Concomitant Alterations in the Hippocampal Neuron Numbers. International Journal of Molecular Sciences 19:8, pages 2461.
Crossref
Crossref
Lukas Frase & Christoph Nissen. (2018) Wer profitiert von Melatonin?. DNP - Der Neurologe & Psychiater 19:4, pages 24-28.
Crossref
Crossref
Yi-Min YuKe-Run GaoHao YuYi-Feng ShenHua-Fang Li. (2018) Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder. Journal of Clinical Psychopharmacology 38:3, pages 226-233.
Crossref
Crossref
Jia-ning Xu, Li-fang Chen, Jun Su, Zhi-li Liu, Jie Chen, Qing-fen Lin, Wei-dong Mao & Dong Shen. (2018) The anxiolytic-like effects of ginsenoside Rg3 on chronic unpredictable stress in rats. Scientific Reports 8:1.
Crossref
Crossref
Yu. P. Sivolap. (2018) Antidepressants: the goals and possibilities of therapy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 118:12, pages 120.
Crossref
Crossref